| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
64,208,000 |
| Market
Cap: |
7.02(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 845 |
| Guru Rank Value : 2.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
101,621 |
113,621 |
| Total Buy Value |
$0 |
$0 |
$9,993,082 |
$11,428,882 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
3 |
| Total Shares Sold |
123,791 |
135,291 |
167,800 |
187,830 |
| Total Sell Value |
$21,991,854 |
$23,517,104 |
$27,973,848 |
$30,315,887 |
| Total People Sold |
6 |
6 |
7 |
7 |
| Total Sell Transactions |
8 |
11 |
25 |
36 |
| End Date |
2025-11-16 |
2025-08-15 |
2025-02-14 |
2024-02-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
2,370 |
9,382 |
|
- |
|
| Gala Renee D |
President & CEO |
• – – |
2026-01-16 |
4 |
D |
$171.16 |
$919,300 |
D/D |
(5,371) |
115,230 |
|
- |
|
| Gala Renee D |
President & CEO |
• – – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,741 |
120,601 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2026-01-16 |
4 |
D |
$171.16 |
$560,549 |
D/D |
(3,275) |
53,339 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,852 |
56,614 |
|
- |
|
| Henderson Mary Elizabeth |
SVP, Technical Operations |
• – – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,116 |
29,624 |
|
- |
|
| Iannone Robert |
EVP, Global Head of R&D & CMO |
• – – |
2026-01-16 |
4 |
D |
$171.16 |
$708,602 |
D/D |
(4,140) |
80,258 |
|
- |
|
| Iannone Robert |
EVP, Global Head of R&D & CMO |
• – – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,699 |
84,398 |
|
- |
|
| Cozadd Bruce C |
Director |
– • – |
2026-01-16 |
4 |
D |
$171.16 |
$2,987,255 |
D/D |
(17,453) |
411,796 |
|
- |
|
| Cozadd Bruce C |
Director |
– • – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
35,917 |
429,249 |
|
- |
|
| Pearce Samantha |
EVP, Chief Commercial Officer |
• – – |
2026-01-16 |
4 |
D |
$171.16 |
$273,685 |
D/D |
(1,599) |
42,993 |
|
- |
|
| Pearce Samantha |
EVP, Chief Commercial Officer |
• – – |
2026-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
3,637 |
44,592 |
|
- |
|
| Henderson Mary Elizabeth |
SVP, Technical Operations |
• – – |
2025-12-09 |
4 |
S |
$169.51 |
$379,366 |
D/D |
(2,238) |
19,508 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2025-12-05 |
4 |
S |
$171.11 |
$797,783 |
D/D |
(4,660) |
7,012 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2025-12-05 |
4 |
OE |
$140.67 |
$633,015 |
D/D |
4,500 |
11,512 |
|
- |
|
| Gala Renee D |
President & CEO |
• – – |
2025-12-05 |
4 |
D |
$166.91 |
$13,353 |
D/D |
(80) |
107,860 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2025-12-02 |
4 |
D |
$173.07 |
$104,361 |
D/D |
(603) |
25,811 |
|
- |
|
| Cozadd Bruce C |
Director |
– • – |
2025-11-26 |
4 |
S |
$177.27 |
$13,780,337 |
D/D |
(77,500) |
393,332 |
|
- |
|
| Cozadd Bruce C |
Director |
– • – |
2025-11-26 |
4 |
OE |
$123.36 |
$9,560,400 |
D/D |
77,500 |
470,832 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2025-11-20 |
4 |
S |
$177.78 |
$607,127 |
D/D |
(3,415) |
20,449 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2025-11-20 |
4 |
OE |
$138.08 |
$471,543 |
D/D |
3,415 |
23,864 |
|
- |
|
| Cozadd Bruce C |
Director |
– • – |
2025-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,506 |
393,332 |
|
- |
|
| Henderson Mary Elizabeth |
SVP, Technical Operations |
• – – |
2025-11-19 |
4 |
D |
$180.40 |
$240,112 |
D/D |
(1,331) |
21,746 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2025-11-18 |
4 |
S |
$180.86 |
$994,728 |
D/D |
(5,500) |
8,893 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2025-11-18 |
4 |
S |
$181.66 |
$968,402 |
D/D |
(5,319) |
7,012 |
|
- |
|
799 Records found
|
|
Page 1 of 32 |
|
|
0.37 (0.34%) 
